一分钟看懂
这是一项关于乳腺癌的I 期 / II 期研究，登记的药物或干预包括BNT323；BNT327，当前状态为招募中。登记地点显示中国蚌埠、长春、成都、重庆等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BNT323；BNT327 · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Bengbu Medical College · 蚌埠
- Jilin Cancer Hospital · 长春
- Sichuan Cancer Hospital · 成都
- Sichuan Provincial People's Hospital · 成都
- The First Affiliated Hospital of Chongqing Medical University · 重庆
- Huizhou First Hospital · 惠州
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Fudan University Shanghai Cancer · 上海
- The Second Affiliated Hospital of Xi an Jiaotong University · 西安
公开的入选条件
- (applicable to all participants and all parts unless otherwise specified):
- * Have pathologically documented BC that:
- Is locally advanced, unresectable or metastatic.
- Has a confirmed HER2 status as determined by the local laboratory as standard of care testing prior to study screening (Part 1, Part 2 Cohorts 2 and 4) or the central laboratory (Part 2, Cohorts 1 and 3) from the most recently collected pre-randomization tumor
- Has a documented history of HER2 expression consistent with the subgroup definitions (i.e., HER2-low, HER2-ultralow, HER2-null, HER2-positive, or TNBC) as per current American Society of Clinical Oncology/College of American Pathologists guidelines.
- * Have measurable disease defined by RECIST v1.1.
- * Has left ventricular ejection fraction ≥55% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization/enrollment.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06827236；登记信息更新于 2026-09-17。